arcoris bio

Executive Summary

Arcoris Bio, a Swiss biotechnology company founded in 2021 and headquartered in Zurich, has developed MUSE® (Multiplex Universal Signal Enhancement), an enzyme-free DNA nanotechnology platform that enables highly sensitive and specific multiplex imaging of proteins and nucleic acids. This platform is designed for applications in immunofluorescence (IF), immunohistochemistry (IHC), and in situ hybridization (FISH), targeting both research and diagnostic markets. By allowing simultaneous detection of multiple biomarkers in a single sample, MUSE® addresses key limitations of current imaging technologies, such as spectral overlap and signal amplification complexity. The company's approach leverages DNA nanostructures to enhance signal without enzymes, offering improved reproducibility and scalability. As a private company with no disclosed funding or valuation, Arcoris Bio is positioned to disrupt the spatial biology and diagnostic imaging space, though it remains at an early commercial stage.

Upcoming Catalysts (preview)

• Q3 2026Commercial launch of MUSE® for IHC applications60% success
• Q4 2026Peer-reviewed publication validating MUSE® performance in multiplex imaging75% success
• H2 2026Strategic partnership with a diagnostics or CRO company for distribution50% success